KR102943105B1 - 막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg - Google Patents

막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg

Info

Publication number
KR102943105B1
KR102943105B1 KR1020207030558A KR20207030558A KR102943105B1 KR 102943105 B1 KR102943105 B1 KR 102943105B1 KR 1020207030558 A KR1020207030558 A KR 1020207030558A KR 20207030558 A KR20207030558 A KR 20207030558A KR 102943105 B1 KR102943105 B1 KR 102943105B1
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207030558A
Other languages
English (en)
Korean (ko)
Other versions
KR20210005602A (ko
Inventor
기드온 그로스
하다스 웨인스타인-마롬
아미트 크로너
Original Assignee
가비쉬-가릴리 바이오 어플리케이션스 리미티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가비쉬-가릴리 바이오 어플리케이션스 리미티드. filed Critical 가비쉬-가릴리 바이오 어플리케이션스 리미티드.
Publication of KR20210005602A publication Critical patent/KR20210005602A/ko
Application granted granted Critical
Publication of KR102943105B1 publication Critical patent/KR102943105B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
KR1020207030558A 2018-03-23 2019-03-22 막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg Active KR102943105B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647084P 2018-03-23 2018-03-23
US62/647,084 2018-03-23
PCT/IL2019/050324 WO2019180724A1 (en) 2018-03-23 2019-03-22 Genetically reprogrammed tregs expressing membrane-bound il-10

Publications (2)

Publication Number Publication Date
KR20210005602A KR20210005602A (ko) 2021-01-14
KR102943105B1 true KR102943105B1 (ko) 2026-03-24

Family

ID=66448601

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030558A Active KR102943105B1 (ko) 2018-03-23 2019-03-22 막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg

Country Status (10)

Country Link
US (1) US20210347843A9 (https=)
EP (1) EP3768699B1 (https=)
JP (2) JP7404331B2 (https=)
KR (1) KR102943105B1 (https=)
CN (1) CN112088164A (https=)
AU (1) AU2019240370B2 (https=)
CA (1) CA3094927A1 (https=)
IL (1) IL277541A (https=)
SG (1) SG11202010454PA (https=)
WO (1) WO2019180724A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220186232A1 (en) * 2019-03-26 2022-06-16 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars
EP4536689A1 (en) * 2022-06-10 2025-04-16 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
EP4289859A1 (en) * 2022-06-10 2023-12-13 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
EP4565702A1 (en) * 2022-08-03 2025-06-11 Migal Galilee Research Institute Ltd. Chimeric membrane-bound cytokines incorporating costimulatory elements for enhancing anti-inflammatory function
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途
CN119331826B (zh) * 2024-12-18 2025-08-05 智在汉青生物科技(浙江)有限公司 用于增强细胞免疫疗法的表达非分泌型il-10的免疫细胞、制备方法及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5275100A (en) * 1999-05-21 2000-12-12 Regents Of The University Of California, The Fluorescent protein indicators
WO2001089286A2 (en) * 2000-05-24 2001-11-29 Cel-Sci Corporation T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders
AU2003241127A1 (en) * 2002-06-12 2003-12-31 Gavish-Galilee Bio Applications Ltd MEMBRANE-ANCHORED Beta2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
US20050048587A1 (en) * 2003-07-17 2005-03-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
CA2739608A1 (en) * 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
AU2013203561B2 (en) * 2009-05-15 2015-11-26 Irx Therapeutics, Inc. Vaccine immunotherapy
EP2457579A1 (en) * 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
ES2612914T3 (es) * 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
MX2018007295A (es) * 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
MY210545A (en) * 2016-04-01 2025-09-30 Kite Pharma Inc Chimeric receptors to flt3 and methods of use thereof
JP7084881B2 (ja) * 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
CN107216395B (zh) * 2017-07-03 2018-07-20 上海科医联创生物科技有限公司 一种tm4sf1特异性嵌合抗原受体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Therapy, Vol.25(10), pp.2254-2269 (2017.10.04.)*

Also Published As

Publication number Publication date
EP3768699A1 (en) 2021-01-27
IL277541A (en) 2020-11-30
JP2024019533A (ja) 2024-02-09
WO2019180724A1 (en) 2019-09-26
US20210040169A1 (en) 2021-02-11
US20210347843A9 (en) 2021-11-11
JP2021519107A (ja) 2021-08-10
EP3768699B1 (en) 2025-11-12
AU2019240370B2 (en) 2024-03-07
SG11202010454PA (en) 2020-11-27
KR20210005602A (ko) 2021-01-14
AU2019240370A1 (en) 2020-11-19
CA3094927A1 (en) 2019-09-26
CN112088164A (zh) 2020-12-15
JP7404331B2 (ja) 2023-12-25

Similar Documents

Publication Publication Date Title
KR102943105B1 (ko) 막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg
AU2019254824B2 (en) Method for enhancing the suppressive properties of Treg cells
JP2025072432A (ja) Ｔｃｒ及びペプチド
ES3057086T3 (en) Car for use in the treatment of hvg disease
US20220119477A1 (en) Tcr and peptides
JP7789666B2 (ja) Ｈｌａ特異的なキメラ抗原受容体
CN110857319B (zh) 一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
TW202146431A (zh) 用於經工程化細胞之嵌合受體
CN113226475A (zh) 改造tcr及其制造方法
WO2022029431A1 (en) Chimeric receptor binding tgf-beta
CN114127287A (zh) 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
CN108456247A (zh) 靶向ny-eso-1的t细胞受体及其用途
US20220364057A1 (en) Engineered regulatory t cell
CN108165568B (zh) 一种培养CD19CAR-iNKT细胞方法及用途
CA3241186A1 (en) Constitutive cytokine receptors
HK40042137A (en) Genetically reprogrammed tregs expressing membrane-bound il-10
US20260028388A1 (en) Recombinant cytokine receptors and methods of use
US20250333697A1 (en) Tethered interleukin-2 recombinant receptors and methods of use
US20250283039A1 (en) Method for maintaining suppressive activity of regulatory t cells
CN121586727A (zh) 组成型细胞因子受体
HK40058915A (en) Tcr and peptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)